Eli Lilly Expands RNA Pipeline with $1.3 Billion Rznomics Hearing Loss Pact

Eli Lilly and Rznomics have entered a global licensing and co-development agreement to create RNA-editing gene therapies for hereditary hearing loss, with the deal potentially valued at over $1.3 billion if all options are exercised123.

The partnership is focused on sensorineural hearing loss, using Rznomics' proprietary trans-splicing ribozyme platform to enable precision RNA therapeutics2.

Rznomics will lead early-stage research and discovery, while Eli Lilly takes on later-stage development and commercialization if the program advances23.

The deal includes up to $1.3 billion in potential payments to Rznomics, as well as separate royalties on future product sales. Specifics about upfront payments were not disclosed23.

This move aligns with Eli Lilly’s strategy to bolster its RNA therapeutics pipeline and signals a significant milestone for Rznomics, advancing its global biotech presence2.

Sources:

1. https://www.bioworld.com/articles/720175-rznomics-in-13b-lilly-pact-to-make-hearing-loss-rna-editor-drug

2. https://www.benzinga.com/25/05/45450675/eli-lilly-collaborates-with-south-korea-based-rznomics-for-rna-editing-therapies-for-hearing-loss-treatment-in-over-13-billion-pact

3. https://www.bioworld.com/articles/720181-rznomics-in-13b-lilly-pact-to-make-hearing-loss-rna-editor-drug